Health and Healthcare

Immuron : IMRN

IMRN

Stock Data

$1.15

$0.09 (8.49%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immunomodulated diseases in Australia, the United States and internationally. The company is headquartered in Carlton, Australia.

All Immuron Articles

2 Articles

Chris Lange | Jul 21, 2020 at 8:51 AM EDT

Why Immuron’s New COVID-19 Study Is a Game Changer

Immuron continued its winning streak on Tuesday after the company announced that its IMM-124E has demonstrated neutralizing activity against the…

Jon C. Ogg | Jun 9, 2020 at 7:16 PM EDT

Can the 800% Gain in Immuron Be Rationalized Very Easily?

The day traders are back at it, chasing stocks on news with very few thoughts about what the fundamentals may…